Xilio Therapeutics Ownership | Who Owns Xilio Therapeutics?

Xilio Therapeutics Ownership Summary

Xilio Therapeutics is owned by 0.78% institutional investors, 28.49% insiders, and 70.73% retail investors. Rivervest venture management is the largest institutional shareholder, holding 5.16% of XLO shares. Vanguard Institutional Extnd Mkt Idx Tr is the top mutual fund, with 0.98% of its assets in Xilio Therapeutics shares.

XLO Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Xilio Therapeutics	0.78%	28.49%	70.73%
Sector	Healthcare Stocks	35.58%	11.87%	52.55%
Industry	Biotech Stocks	35.75%	11.83%	52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Rivervest venture management	1.44M	5.16%	$1.37M
Takeda pharmaceutical	1.48M	1.53%	$1.24M
Vanguard group	1.26M	0.87%	$803.64K
Gilead sciences	650.39K	0.78%	$5.47M
Balyasny asset management	198.86K	0.27%	$135.20K
Blackrock	66.42K	0.24%	$62.93K
Raymond james & associates	38.83K	0.14%	$36.79K
Susquehanna group, llp	49.09K	0.08%	$46.88K
Charles schwab investment management	11.93K	0.04%	$11.30K
Two sigma securities	32.13K	0.03%	$27.08K

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Rivervest venture management	1.44M	20.01%	$1.37M
Takeda pharmaceutical	1.48M	7.59%	$1.24M
Gilead sciences	650.39K	0.26%	$5.47M
Two sigma securities	32.13K	0.00%	$27.08K
Balyasny asset management	198.86K	0.00%	$135.20K
Two sigma advisers, lp	29.69K	0.00%	$25.02K
Point72 asset management	-	-	-
Engineers gate manager lp	-	-	-
Prelude capital management	-	-	-
Mariner	-	-	-

Top Buyers

Holder	Shares	% Assets	Change
Susquehanna group, llp	49.09K	-	49.09K
Raymond james & associates	38.83K	-	38.83K
Two sigma securities	32.13K	0.00%	32.13K
Two sigma advisers, lp	29.69K	0.00%	29.69K
Blackrock	66.42K	-	21.06K

Top Sellers

Holder	Shares	% Assets	Change
Gilead sciences	650.39K	0.26%	-8.46M
Bain capital life sciences investors	-	-	-7.37M
Frazier life sciences management	-	-	-5.92M
Point72 asset management	-	-	-4.00M
Rock springs capital management lp	-	-	-3.00M

New Positions

Holder	Shares	% Assets	Change	Value
Susquehanna group, llp	49.09K	-	49.09K	$46.88K
Raymond james & associates	38.83K	-	38.83K	$36.79K
Two sigma securities	32.13K	0.00%	32.13K	$27.08K
Two sigma advisers, lp	29.69K	0.00%	29.69K	$25.02K

Sold Out

Holder	Change
Qube research	-4.00
Jpmorgan chase	-62.00
Wells fargo & company/mn	-108.00
Ubs group	-203.00
Citigroup	-258.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	1	-97.30%	650,389	-98.36%	-	0.10%	-	-100.00%	1	-80.00%
Dec 31, 2025	22	-38.89%	20,254,500	-8.15%	14	2.69%	8	-27.27%	3	-
Sep 30, 2025	36	5.88%	22,051,916	-1.34%	22	2.55%	11	10.00%	3	-72.73%
Jun 30, 2025	34	3.03%	23,770,263	21.47%	31	4.64%	11	-21.43%	10	42.86%
Mar 31, 2025	35	-	22,528,206	-12.87%	30	1.82%	14	-6.67%	7	16.67%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Institutional Extnd Mkt Idx Tr	58.91K	0.98%	-
Vanguard Total Stock Mkt Idx Inv	51.70K	0.86%	-
Fidelity Extended Market Index	21.69K	0.36%	-120.21K
Abante Quant Value FI	15.63K	0.34%	15.63K
Vanguard Instl Ttl Stk Mkt Idx InstlPls	13.05K	0.22%	-
iShares Micro-Cap ETF	59.99K	0.12%	-
Spartan Extended Market Index Pool F	4.89K	0.08%	-32.99K
Bridgeway Ultra-Small Company Market	56.08K	0.08%	-
Fidelity Total Market Index	4.51K	0.08%	-58.69K
Spartan Extended Market Index Pool E	30.66K	0.06%	1.54K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Mar 26, 2026	Shannon James Samuel	-	Buy	$43.95K
Feb 13, 2026	GILEAD SCIENCES, INC.	-	Buy	$373.90
Jan 02, 2026	Brennan Kevin M.	SVP, FINANCE AND ACCOUNTING	Sell	$1.17K
Jan 02, 2026	Frankenfield Christopher James	Chief Financial Officer	Sell	$4.52K
Jun 17, 2025	Shannon James Samuel	-	Buy	$17.21K

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	-	-
2026 Q1	2	2
2025 Q4	-	-
2025 Q2	7	-
2025 Q1	-	2

XLO Ownership FAQ

Who Owns Xilio Therapeutics?

Xilio Therapeutics shareholders are primarily institutional investors at 0.78%, followed by 28.49% insiders and 70.73% retail investors. The average institutional ownership in Xilio Therapeutics's industry, Biotech Stocks , is 35.75%, which Xilio Therapeutics falls below.

Who owns the most shares of Xilio Therapeutics?

Xilio Therapeutics’s largest shareholders are Rivervest venture management (1.44M shares, 5.16%), Takeda pharmaceutical (1.48M shares, 1.53%), and Vanguard group (1.26M shares, 0.87%). Together, they hold 7.57% of Xilio Therapeutics’s total shares outstanding.

Does Blackrock own Xilio Therapeutics?

Yes, BlackRock owns 0.24% of Xilio Therapeutics, totaling 66.42K shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 62.93K$. In the last quarter, BlackRock increased its holdings by 21.06K shares, a 46.44% change.

Who is Xilio Therapeutics’s biggest shareholder by percentage of total assets invested?

Rivervest venture management is Xilio Therapeutics’s biggest shareholder by percentage of total assets invested, with 20.01% of its assets in 1.44M Xilio Therapeutics shares, valued at 1.37M$.

Who is the top mutual fund holder of Xilio Therapeutics shares?

Vanguard Institutional Extnd Mkt Idx Tr is the top mutual fund holder of Xilio Therapeutics shares, with 0.98% of its total shares outstanding invested in 58.91K Xilio Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools